Back to Search
Start Over
[68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas.
- Source :
- Scientific Reports; 9/28/2022, Vol. 12 Issue 1, p1-14, 14p
- Publication Year :
- 2022
-
Abstract
- Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[<superscript>68</superscript>Ga]FAPI-PET/CT on target-volume-definition and posttreatment-[<superscript>68</superscript>Ga]FAPI-PET/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[<superscript>68</superscript>Ga]FAPI-PET/CT±[<superscript>18</superscript>F]FDG-PET/CT were included from 01.01.2020 to 01.03.2022. MTV and SUV<subscript>max</subscript> were separately generated based on [<superscript>68</superscript>Ga]FAPI- and [<superscript>18</superscript>F]FDG-PET/CT-images. A [<superscript>68</superscript>Ga]FAPI- and [<superscript>18</superscript>F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [<superscript>68</superscript>Ga]FAPI-PET/CT and [<superscript>18</superscript>F]FDG-PET/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUV<subscript>max_lesion</subscript>/SUV<subscript>mean_background</subscript>] for individual timepoints t<subscript>1</subscript> and t<subscript>2</subscript> revealed significant higher values for [<superscript>68</superscript>Ga]FAPI compared to [<superscript>18</superscript>F]FDG (t<subscript>1</subscript>, p = 0.008; t<subscript>2</subscript>, p = 0.005). Intermodality comparison of radiation-therapy-plans showed that [<superscript>68</superscript>Ga]FAPI-based planning resulted in D100% = 97.2% and V95% = 98.8% for the [<superscript>18</superscript>F]FDG-MTV. [<superscript>18</superscript>F]FDG-based-planning resulted in D100% = 35.9% and V95% = 78.1% for [<superscript>68</superscript>Ga]FAPI-MTV. [<superscript>18</superscript>F]FDG-based-planning resulted only in 2 patients in V95% > 95% for [<superscript>68</superscript>Ga]FAPI-MTV, and in 1 patient in D100% > 97% for [<superscript>68</superscript>Ga]FAPI-MTV. GTV-coverage in terms of V95% was 76.4% by [<superscript>18</superscript>F]FDG-based-planning and 99.5% by [<superscript>68</superscript>Ga]FAPI-based-planning. Pretreatment [<superscript>68</superscript>Ga]FAPI-PET/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [<superscript>18</superscript>F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [<superscript>68</superscript>Ga]FAPI-imaging. Complementary [<superscript>68</superscript>Ga]FAPI- and [<superscript>18</superscript>F]FDG-imaging enhance treatment-response-assessment. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 12
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Scientific Reports
- Publication Type :
- Academic Journal
- Accession number :
- 159382060
- Full Text :
- https://doi.org/10.1038/s41598-022-20447-6